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Myosin VI is the only known molecular motor that
moves toward the minus ends of actin filaments;
thus, it plays unique roles in diverse cellular pro-
cesses. The processive walking of myosin VI on actin
filaments requires dimerization of the motor, but the
protein can also function as a nonprocessive mono-
mer. The molecular mechanism governing the mono-
mer-dimer conversion is not clear.We report the high-
resolution NMR structure of the cargo-free myosin VI
cargo-binding domain (CBD) and show that it is
a stable monomer in solution. The myosin VI CBD
binds to a fragment of the clathrin-coated vesicle
adaptor Dab2with a high affinity, and the X-ray struc-
ture of the myosin VI CBD in complex with Dab2
reveals that the motor undergoes a cargo-binding-
mediated dimerization. The cargo-binding-induced
dimerization may represent a general paradigm for
the regulation of processivity for myosin VI as well
as other myosins, including myosin VII and myosin X.
INTRODUCTION
Myosins are actin-based molecular motors that play vital roles in
diverse cellular processes ranging from muscle contraction to
intracellular transport (Foth et al., 2006; O’Connell et al., 2007;
Sellers, 2000). Myosin VI is the only known motor that transports
cargoes to the minus ends of the actin filaments (Mermall et al.,
1994; Wells et al., 1999). Originally discovered as an F-actin-
binding protein in Drosophila, myosin VI has subsequently
been identified in many other species (Baker and Titus, 1997;
Hasson and Mooseker, 1994; Hasson et al., 1996; Kellerman
and Miller, 1992). Myosin VI-mediated cargo transport is essen-
tial for a host of cellular processes, including clathrin-dependent
endocytosis, the maintenance of the cis- and trans-Golgi
network and exocytosis at the Golgi complexes, and the asym-
metric distribution of cellular components in polarized cells
(see reviews, Buss and Kendrick-Jones, 2008; Buss et al.,
2004; Sweeney and Houdusse, 2007). In addition to its transport-
ing roles, myosin VI also serves as an anchor that supports
cellular architectures by physically connecting cytoskeletonswith its binding targets, such as membranes. As an anchor,
myosin VI is indispensable for the development and mainte-
nance of highly organized cellular structures, such as the stereo-
cilia of hair cells in ears (Hasson et al., 1997; Seiler et al., 2004),
the leading edges of migrating cells (Geisbrecht and Montell,
2002), and the establishment and maintenance of the apico-
basal polarity of epithelia (Maddugoda et al., 2007). In addition
to myosin VI, other unconventional myosins (e.g., myosin VII,
myosin X, and myosin XV) can also function both as transporters
and as anchors (Knight et al., 2005; Yang et al., 2006). However,
the molecular mechanisms dictating this functional dichotomy of
the unconventional myosins are largely unknown.
Myosin VI contains an N-terminal motor domain followed by
a short neck (also called the lever arm), a hypothetical coiled-
coil domain in the middle, and a C-terminal globular cargo-
binding domain (CBD) (Figure 1A). Recent structural and
biochemical studies of the motor domain have revealed that
a unique insertion between the motor domain and the neck
region confers the reverse moving directionality to myosin VI
(Bryant et al., 2007; Menetrey et al., 2005). The structural rear-
rangement of this insertion, together with the neck, also provides
a partial explanation for the large power-stroke of myosin VI (Me-
netrey et al., 2007, 2008). Recent studies of the putative coiled-
coil region indicate that it forms an extended monomeric helix
instead of the previously expected dimeric coiled-coil (Rock
et al., 2001; Spink et al., 2008). This finding provides a plausible
explanation for the unexpectedly large step size (36 nm) of
myosin VI but also raises an important question concerning the
dimerization mechanism of the motor.
The C-terminal CBD of myosin VI recognizes and selects its
binding cargoes (Buss et al., 2004; Sweeney and Houdusse,
2007). Several adaptor proteins have been reported to interact
specifically with the CBD, thus defining the specific subcellular
functions of myosin VI: an endocytic adaptor protein Disabled-
2 (Dab2), which links myosin VI to clathrin-coated vesicles at
the early stages of endocytosis (Buss et al., 2001; Inoue et al.,
2002; Morris et al., 2002); GIPC, another endocytic adaptor,
which bridges myosin VI to the clathrin-uncoated vesicles for
the late stages of endocytosis (Aschenbrenner et al., 2003;
Bunn et al., 1999; Naccache et al., 2006; Reed et al., 2005);
and a Golgi resident adaptor optineurin, which provides a linkage
between myosin VI and the Golgi complex during biosynthetic
exocytosis (Au et al., 2007; Sahlender et al., 2005). In addition
to cargo recognition, the myosin VI CBD has recently beenCell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc. 537
Figure 1. Structure of the Apo-Myosin VI CBD
(A) Schematic diagram showing the domain organization of myosin VI.
(B) Amino acid sequence alignment of the CBD from various species of myosin VI. In this alignment, the completely and highly conserved residues are shown in
red and green, respectively. The secondary structure derived from the NMR structure of the domain is indicated in the alignment. The residues forming the binding
sites I and II for Dab2 are highlighted with dots and triangles underneath the sequences, respectively. Leu1209, which was substituted with Lys for the structure
determination of the apo-CDB, is indicated with an asterisk at the top of the alignment.
(C, left) An overlay plot of a selected region of the 1H-15N HSQC spectrum of the wild-type myosin VI CBD without and with the addition of 0.5% CHAPS in the
sample buffer, showing significant chemical shift differences of the domain induced by the binding of CHAPS. (C, right) An overlay plot of the same region HSQC
spectrum of the wild-type CBD with that of the L1209K-CBD, showing that the mutation does not alter the conformation of the domain.
(D) Stereo view showing the overlay of the backbones of the final 20 NMR structures of myosin VI L2K-CBD.
(E) Ribbon diagram representation of the apo-myosin VI CBD.shown to be involved in the dimerization of myosin VI (Spudich
et al., 2007). Electron microscopy (EM) studies of myosin VI
in vitro showed that purified myosin VI can form dimers at high538 Cell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc.concentrations, and this clustering-induced dimerization is
somewhat inhibited by its CBD (Park et al., 2006). In contrast,
a fluorescence resonance energy transfer-based assay in vivo
demonstrated that myosin VI forms dimers on the surface of
transport vesicles in a CBD-dependent manner (Altman et al.,
2007). Myosin VI needs to forma processive dimer for its transport
function (Altman et al., 2007; Park et al., 2006; Spink et al., 2008).
Intriguingly, it has been shown that purified native myosin VI exists
as a nonprocessive monomer in solution (Lister et al., 2004), and
the monomeric myosin VI has been proposed to function mainly
as an anchor (Buss et al., 2004). Therefore, the elucidation of
the molecular mechanism governing the monomer-dimer conver-
sion of myosin VI represents a task crucial to understanding the
cellular functions of myosin VI as well as other unconventional
myosins.
Here, we describe our 8 year journey in the elucidation of the
myosin VI cargo recognition mechanism. The solution structure
of the monomeric apo-myosin VI CBD solved in this work reveals
that myosin VI exists as a stable monomer in the absence of
cargoes. The crystal structure of the myosin VI CBD/Dab2
complex shows that the myosin VI CBD forms a cargo-induced
dimer, suggesting that the motor undergoes a cargo binding-
dependent monomer-to-dimer conversion. This cargo binding-
mediated monomer-to-dimer conversion mechanism adopted
by myosin VI may be shared by other unconventional myosins,
such as myosin VII and myosin X.
RESULTS
Structural Determination of the Apo-Form Myosin
VI CBD
We initiated biochemical and structural characterizations of the
myosin CBD when this domain was implicated in cargo selec-
tions (Inoue et al., 2002; Morris et al., 2002; Wu et al., 2002).
The entire myosin VI CBD contains 200 residues, and the
N-terminal 1/3 of this 200 residue fragment was shown to bind
to lipid membranes and cargoes such as GIPC and optineurin
(Reed et al., 2005; Sahlender et al., 2005; Spudich et al., 2007).
The myosin VI CBD studied in detail here corresponds to the
C-terminal 2/3 of the entire tail domain (residues 1137–1265).
Amino acid sequence alignment analysis showed that the
myosin VI CBD is highly conserved throughout its evolution,
with no recognizable protein domains known to date and no
homologous sequences in other proteins (Figure 1B). Our initial
biochemical analysis showed that the myosin VI CBD forms
a stable monomer at low concentrations (<0.2 mM) in solution,
with a well-folded tertiary structure as indicated by the well-
dispersed NMR spectrum of the domain (Figure S1A available
online). Unfortunately, the NMR spectra of the CBD deteriorated
progressively with the increase of its concentration due to
nonspecific sample aggregation (Figure S1B). Extensive efforts
in trying to obtain crystals of the CBD were not successful.
Systematic NMR-based sample condition screenings with
various buffers, salts, and additives revealed that the inclusion
of 0.5%–1% CHAPS in the sample buffer significantly improved
the quality of the CBD spectra (Figure S1C), suggesting that the
domain tends to aggregate via hydrophobic interactions at
elevated concentrations. Due to technical difficulties, we were
only able to determine the solution structure of the myosin VI
CBD in the presence of CHAPS by NMR spectroscopy at a low
resolution (data not shown). Nevertheless, this low-resolutionstructure served as a template for us to design strategies for ob-
taining the high-resolution structure of the domain. Additionally,
the large chemical shift changes of the CBD induced by CHAPS
binding indicated that the CBD structure determined in the pres-
ence of CHAPS may not represent its bona fide structure in its
apo-form (Figures 1C and S2A). Guided by the solution structure
of the CBD in the presence of CHAPS and aided by the NMR-
based sample condition screenings, we tested a large number
of point mutations of the CBD in an attempt to disrupt the concen-
tration-dependent aggregation observed in the wild-type protein.
One of the mutants tested, with Leu1209 substituted with Lys (de-
noted as ‘‘L2K’’-CBD), displayed an excellent NMR spectrum
even at a concentration of 1 mM (Figure S1D). Importantly,
the spectrum of the L2K-CBD overlaps very well with that of the
wild-type protein except for a few residues surrounding
Leu1209, indicating that the substitution of Leu1209 with Lys
did not introduce significant changes to the structure of the
myosin VI CBD (Figures 1C and S2B).
We next determined the high-resolution structure of L2K-CBD
using NMR spectroscopy. The overall structure of the CBD is
well defined except for the N and C termini and the loop between
the first and the second b strands (Figure 1D and Table S1). The
myosin VI CBD contains four b strands (bA–bD) and six a helices
(aA–aF). The four b strands form an antiparallel b sheet, which
forms the core of the domain. One side of the b sheet is covered
by three helices (aD–aF), which pack with each other perpendic-
ularly; the other side of the sheet is largely exposed to the solvent
with a short aC helix capped at one of its edges (Figure 1E). No
folds similar to the myosin VI CBD were found in the Protein Data
Bank (PDB) when searching with the Dali algorithm (http://www.
ebi.ac.uk/dali/). Interestingly, the packing between the helices
(aC and aD–aF) and the b sheet is limited to one end (arbitrarily
referred to as the up-half) of the b sheet, leaving the lower half
of the b sheet completely exposed (Figures 1E and S3). A short
and somewhat mobile helix (aB) connects the bA and bB strands
at the extreme end of the lower half of the CBD b sheet (Figures
1D and 1E). Analysis of the surface properties of the myosin VI
CBD showed that the domain contains a prominent hydrophobic
surface located at one face of the lower half of the b sheet
(Figures 1E and S3). This hydrophobic surface is responsible
for the concentration-dependent aggregation of the wild-type
CBD. The structure also explains why the L2K mutation signifi-
cantly weakens such hydrophobic interactions without altering
the overall structure of myosin VI CDB (Figures S3A and S3B).
This L2K mutation has been extremely valuable in the structure
determination of the apo-form myosin VI CBD. However, the
caveat of the mutation is that it essentially prevented the CBD
from binding to its targets (see below for details).
Dab2Binds to theMyosin VI CBDvia anExtendedRegion
within Its C-Terminal Tail
The best known myosin VI CBD-binding partner known to date is
Disabled-2 (Dab2) (Inoue et al., 2002; Mishra et al., 2002; Morris
et al., 2002; Morris and Cooper, 2001). In view of the critical role
of the myosin VI/Dab2 interaction in clathrin-coated vesicle-
mediated endocytosis(Mishra et al., 2002; Morris et al., 2002),
we decided to characterize this interaction in detail. Dab2 is
composed of an N-terminal PTB domain and a long C-terminalCell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc. 539
Figure 2. The Myosin VI CBD Binds to an Extended Fragment of Dab2 with High Affinity
(A) Amino acid sequence alignment of the Dab2 myosin VI interaction region (MIR) with the same color coding as in Figure 1B. The two a helices of the Dab2 MIR
are indicated. The Dab2 MIR residues interacting with the residues from sites I and II of the myosin VI CBD are highlighted with dots and triangles underneath the
sequences, respectively.
(B, top) An overlay plot of a selected region of the 1H-15N HSQC spectrum of the apo-myosin VI CBD and the domain saturated with the N-terminal half of the MIR
fragment containing only the aA0 helix (residues 675–695), showing significant chemical shift changes of the myosin CBD induced by the N-half MIR peptide
binding. (B, bottom) An overlay plot of the same region of HSQC spectra of the CBD bound to the N-half and the complete Dab2 MIR fragments, showing
that inclusion of the aB0 helix of the Dab2 MIR induces additional chemical shift changes to the myosin VI CBD.
(C) ITC-based measurements of the bindings of various Dab2 fragments to the wild-type myosin VI CBD. The details of the Dab2 MIR fragments used in the
binding assay and the fitted dissociation constants with standard errors are indicated in each panel.tail with no recognizable domains (Figure 2A). Dab2 has been
shown to bind to myosin VI via its C-terminal tail. It was shown
that substitution of the ‘‘682SYF684’’-motif within this Dab2
C-terminal tail with an ‘‘AAA’’ cassette abolished Dab2’s binding
to the GST-fused CBD of myosin VI (Morris et al., 2002). We
confirmed the direct interaction between the myosin VI CBD
and the entire C-terminal tail of the wild-type Dab2 and verified
that the 682SYF684-motif of Dab2 is absolutely required for binding
to myosin VI (data not shown). A 21 residue synthetic peptide
comprising residues 675–695 of Dab2 was used for detailed
characterization of the interaction between Dab2 and myosin
VI. The boundaries of the Dab2 peptide were chosen based on
the following findings: further extension to the N-terminal end
beyond residue 675 did not further increase the binding affinity
of Dab2 to myosin VI (data not shown), and the C-terminal end
was chosen because it was shown that the ‘‘699DFD701’’-motif
of Dab2 was not required for myosin VI binding (Morris et al.,
2002). NMR-based titration experiments showed that the Dab2
peptide indeed binds to the myosin VI CBD with a 1:1 stoichiom-
etry. An ITC-based assay showed that the 21 residue Dab2
peptide binds to the myosin VI CBD with a dissociation constant
(KD) of 0.5 mM (Figure 2C). We believed that this 21 residue
peptide most likely represented the complete myosin VI-binding540 Cell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc.domain of Dab2, and we used NMR and X-ray methods to try to
determine the structure of the myosin VI CBD in complex with this
21 residue peptide. However, we were never able to prepare
a wild-type CBD/Dab2 peptide complex that was suitable for
NMR-based structure determination. Extensive screening for
crystals of the complex also failed.
We decided to revisit the interaction between the myosin VI
CBD and Dab2 using longer fragments of Dab2. Powered by
the exquisite sensitivity of NMR chemical shifts in response to
target bindings, we discovered that addition of a Dab2 fragment
with a C-terminal extension covering the 699DFD701-motif (resi-
dues 675–713) induced additional chemical shift changes to
a number of residues in the myosin VI CBD (Figure 2B, bottom
panel and Figure S4), indicating that the 699DFD701-motif, previ-
ously identified to be dispensable for myosin VI binding (Morris
et al., 2002), is actively involved in the Dab2/myosin VI interac-
tion. Detailed chemical shift perturbation analysis showed that
the binding of the 21 residue Dab2 peptide induced chemical
shift changes limited to one side of the CBD b sheet. This 21
residue Dab2 binding side of the myosin VI CBD b sheet (referred
to as ‘‘site I,’’ Figures S4A and S4B) is highly hydrophobic
(Figure S3B) and complements the hydrophobic nature of the
N-terminal half of the longer Dab2 fragment (Figure 2A).
Table 1. Statistics of Data Collection and Model Refinement of the Myosin VI CBD/Dab2 MIR Complex
Data Collection
Data Sets Native NaI
Space group P21 P21
Unit cell parameters (A˚) a = 69.2, b = 70.0, c = 78.5 b = 98.0 a = 69.2, b = 70.0, c = 78.5 b = 98.3
Resolution range (A˚) 302.2 (2.322.2) 302.6 (2.742.6)
No. of total reflections 135314 (18948) 183092 (26377)
No. of unique reflections 36631 (5217) 23184 (3348)
I/s 14.6 (2.3) 16.0 (2.6)
Completeness (%) 97.0 (95.3) 99.9 (100.0)
Rmerge (%)
a 8.4 (54.8) 15.2 (70.3)
Structure Refinement
Resolution (A˚) 302.2 (2.2572.2)
Rcryst/Rfree (%)
b 18.9 (25.0)/25.1 (31.9) rmsd bonds (A˚)/angles () 0.009/1.09
No. of reflections No. of atoms
working set 34798 protein atoms 5108
test set 1833 water molecules 266
Average B factor (A˚2) Ramachandran plot
main chain 31.2 most favored regions (%) 96.2
side chain 32.7 additionally allowed (%) 3.8
water 30.1 generously allowed (%) 0.0
Numbers in parentheses represent the value for the highest resolution shell.
Rfree = STjjFobsj  jFcalcjj/STjFobsj, where T is a test data set of about 5% of the total reflections randomly chosen and set aside prior to refinement.
a Rmerge =
PjIi  Imj/
P
Ii, where Ii is the intensity of the measured reflection and Im is the mean intensity of all symmetry-related reflections.
b Rcryst = SjjFobsj  jFcalcjj/SjFobsj, where Fobs and Fcalc are observed and calculated structure factors.Extending the Dab2 peptide to cover the 699DFD701-motif (resi-
dues 675–713) induced additional chemical shift changes to
the residues located at the opposite side of the myosin VI CBD
b sheet (referred to as ‘‘site II,’’ Figures S4C and S4D), which is
rich in positively charged residues (Figure S3B) and matches
well with a cluster of the negatively charged residues at the
C-terminal half of the longer Dab2 fragment (Figure 2A). Taken
together, the above biochemical and spectroscopic studies
reveal that the myosin VI CBD contains two discrete Dab2-
binding sites located at the two sides of the myosin VI CBD
b sheet (Figure S4), and that a 39 residue fragment of Dab2 is
directly involved in myosin VI binding. The binding affinity of
this 39 residue extended Dab2 fragment to the myosin VI CBD
(KD 80 nM) is about five times higher than the 21 residue
Dab2 peptide (Figure 2C). Further extension at the C-terminal
end of this 39 residue Dab2 fragment did not increase its binding
affinity to the myosin VI CBD (Figure 2C), indicating that this 39
residue Dab2 fragment (instead of the 21 residue Dab2 peptide
selected initially) represents the complete myosin VI-binding
region of Dab2. We referred to this myosin VI-interacting region
as MIR (myosin VI interaction region, Figure 2A). It is noted that
the Dab2 MIR sequence is also found in Dab1; this explains
why myosin VI also binds to Dab1 (Morris et al., 2002). Addition-
ally, the MIR sequence is highly conserved within the Dab family
proteins throughout their evolution, indicating that the myosin VI/
Dab2 interaction (hence myosin VI-mediated endocytosis) char-
acterized here is a conserved molecular process throughout the
evolution.Dab2 Binding-Mediated Dimerization of Myosin VI
We next wanted to determine, by either NMR or X-ray methods,
the structure of myosin VI in complex with the complete Dab2
MIR. Obviously, we needed to use the wild-type myosin VI
CBD instead of its L2K mutant to prepare the complex. However,
the concentration-dependent aggregation of the wild-type
myosin VI CBD prevented us from making stable and homoge-
neous complex samples (as indicated by the 1H-15N HSQC
spectra of the complex) by either mixing it with the Dab2 MIR
or coexpressing the two proteins in bacteria. Extensive attempts
to grow crystals of the myosin VI CBD/Dab2 MIR complexes
using the mixed or coexpressed samples were not successful
either, likely due to the sample heterogeneity. To overcome the
above problem, we fused the Dab2 MIR peptide to either the
N- or the C-terminal end of the myosin VI CBD, hoping that
the fused proteins would be strictly 1:1 stoichiometric between
the CBD and the MIR. One of the myosin VI-Dab2 fusion proteins
with the MIR peptide fused to the C terminus of the CBD using
a 15 residue Gly-Ser flexible linker together with a thrombin
cleavage sequence in the middle was highly soluble and stable.
The single chain fusion protein was, however, heterogeneous in
its conformation as indicated by its NMR spectrum (Figure S5A).
The NMR spectrum of the fusion protein after thrombin cleavage
was highly homogenous and well dispersed at protein concen-
trations up to 1.5 mM (Figure S5B), indicating that a homoge-
nous and stoichiometric myosin VI CBD/Dab2 MIR complex
was successfully prepared using this approach. High-quality
crystals (Table 1) of the myosin VI CBD/Dab2 MIR complexCell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc. 541
were readily obtained in several crystallization buffer conditions
using the complex sample prepared as described above.
The structure of the myosin VI CBD/Dab2 MIR complex was
determined by preparing iodine derivatives of the complex crys-
tals (Table 1). The most striking finding of the myosin VI CBD/
Dab2 MIR complex is that the myosin VI CBD forms a symmetric
dimer that is tethered by two molecules of the Dab2 MIR (Figures
3A and 3B). In the complex, the myosin VI CBD adopts a similar
conformation to the apo-form protein, except that the flexible
N-terminal helix (aA) is missing in the complex. The Dab2 MIR
forms two helices (aA0 and aB0), corresponding to the N-terminal
and C-terminal halves of the MIR (Figures 2A and 3A). The N-
terminal helix (aA0) of the Dab2 MIR binds to site I of one molecule
of the myosin VI CBD, and the C-terminal helix (aB0) of the same
Dab2 MIR binds to site II of the other CBD in the complex. The
two CBD molecules in the myosin VI/Dab2 complex do not phys-
ically contact each other. Therefore, the formation of the myosin
VI dimer in the complex is exclusively induced by the binding of
Dab2. The high-quality electron density map at the crossover
points of the two Dab2 MIR molecules excluded the possibility
of mis-tracing the Dab2 MIR chains (Figure 3C). The myosin VI/
Dab2 complex structure solved here provides a definitive picture
showing the cargo binding-mediated dimerization of myosin VI.
Figure 3. The Overall Structure of the
Myosin VI CBD/Dab2 MIR Complex
(A) Ribbon diagram representations showing the
Dab2 MIR-induced dimerization of the myosin VI
CBD. In this diagram, the myosin CBD is drawn
in green and two Dab2 MIR fragments are colored
in purple and orange.
(B) Surface diagram showing the binding surface
of the Dab2 MIR on the myosin VI CBD.
(C) The electron density map of the Dab2 MIR in
the myosin VI CBD/Dab2 MIR complex. The green
and blue ribbons are partial b strands from the
myosin CBD in the complex.
We verified that the dimeric myosin VI
CBD/Dab2 complex observed in the
crystal structure also exists in solution.
The myosin VI CBD/Dab2 complex inter-
acted nonspecifically with beads in gel
filtration columns (i.e., analytical gel filtra-
tion cannot be used to assess the molec-
ular mass of the complex; data not
shown). As an alternative approach, we
used a site-specific chemical crosslinking
approach to probe the dimer state of the
complex. The structure of the dimeric
myosin VI CBD/Dab2 MIR complex
shows that L1225 in the aC/aD loop of
the CBD represents the closest neigh-
boring residues of the two noncontacting
CBD molecules in the complex (a distance
of 4.4 A˚ between Cg of the two Leu resi-
dues) (Figures 3 and 4A). We reasoned
that the substitution of L1225 with Cys
would specifically promote the formation
of the disulfide bond-mediated CBD dimer of the CBD/MIR
complex, as the distance of the two Cys side chains in the
complex is nearly ideal for spontaneous disulfide bond formation.
In contrast, neither the apo-CBD nor the CBD in complex with
the short Dab2 MIR containing only aA0 would form specific disul-
fide-mediated CBD dimers with the same L1225C mutation.
Exactly as we have predicted, no CBD dimer could be observed
in the nonreducing SDS-PAGE for the apo-CDB(L1225C) and
CDB(L1225C) saturated with the short Dab2 MIR peptide con-
taining only aA0. In contrast, CBD(L1225C) was found to form
a quantitative dimer in complex with the longer form of the
Dab2 MIR, with or without the addition of the dimer-promoting
catalyst [Cu(Phen)3]
2+ (Figure 4B). The addition of DTT completely
disrupted this disulfide-mediated covalent dimer of the myosin VI
CBD as observed on the SDS-PAGE. Therefore, we conclude that
the dimeric myosin VI CBD/Dab2 MIR complex structure revealed
in the crystal structure also exists in solution. The second helix
(aB0) of the Dab2 MIR is absolutely required for the Dab2-medi-
ated dimerization of the myosin VI CBD.
Interface between the Myosin VI CBD and the Dab2 MIR
As revealed by both our NMR and X-ray crystallographic studies,
the myosin VI CBD contains two discrete Dab2-binding sites,542 Cell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc.
namely, site I and site II (Figure 5). Site I is mainly formed by
hydrophobic residues from bA, bB, and aC of the myosin VI
CBD, which are located at one face of the CBD b sheet, and
accommodates aA0 of the Dab2 MIR chiefly via hydrophobic
interactions (Figures 5A and 5B). The side chains of F680,
Y683, F684, and V688 (the ‘‘FxxYF’’-motif in aA0) of the Dab2
MIR contact extensively with I1153, F1155, W1173, L1209,
T1214, and L1216 in site I of the myosin VI CBD (Figures 5A
and 5B). In addition, the backbones of I690 and P691 of the
Dab2 MIR form a mini-antiparallel b sheet with the C-terminal
end of the CBD bA. The side chains of I690 and P691 of the
MIR interact with the side chains of I1156 and F1155 from the
CBD, respectively. The single point mutation in site I (L1209 to
K, the mutant used for the structural determination of the apo-
myosin VI CBD) dramatically decreased its Dab2 binding
(Figure 5D), indicating that the interaction in site I plays a domi-
Figure 4. Dab2 MIR Binding-Induced Dimerization of Myosin VI
in Solution
(A) Combined ribbon (myosin VI CBD) and surface (Dab2 MIR) representation
of the mysoin VI/Dab2 complex. The side chains of Leu1225 immediately
N-terminal to aD (shown in the explicit atomic model) are the closest residues
of the two myosin CBD molecules in the complex. Leu1225 was substituted
with Cys for disulfide-mediated crosslinking experiments in probing the dimer
structure of the myosin VI CBD in the complex.
(B) Disulfide-mediated formation of the covalent myosin VI CBD dimer requires
binding of the entire Dab2 MIR fragment containing both aA0 and aB0 helices.
Neither apo-CBD nor CBD saturated with the N-half of the Dab2 MIR contain-
ing only aA0 (MIR aA0) could form a disulfide-mediated dimer, as assessed by
nonreducing SDS-PAGE. The figure also showed that inclusion of the disulfide
bond-promoting reagent, [Cu(phen)3]SO4, converted the CBD into a quantita-
tive dimer when the domain was saturated with the Dab2 MIR. Finally, the
disulfide-mediated the myosin VI CBD dimer induced by the binding of the
Dab2 MIR can be completely reversed by the addition of an excess amount
of DTT in the SDS-PAGE sample buffer. The gel was stained with Coomassie
blue dye. The slightly lager CBD mass shown in the complex with the MIR is
due to extra residues carried over after cleavage of the CBD-MIR fusion
protein by thrombin.nant role in myosin VI/Dab2 binding. Site II is at the opposite
face of the CBD b sheet with respect to site I, and the residues
in site II bind to aB0 of the Dab2 MIR via both charge-charge
and hydrophobic interactions (Figures 5A and 5C). The positively
charged R1152 and K1170 from the myosin VI CBD form a
charge-charge interaction network with D696, D698, D699, and
D701 from the Dab2 MIR. The N31 of W1172 from the CBD forms
a hydrogen bond with the carboxyl oxygen of D698 (Figure 5C).
The side chains of A702, L705, L706, and I709 of the Dab2 MIR
interact with the hydrophobic side chains of W1172, L1188,
P1190, P1194, and I1232 from the myosin VI CBD. Interestingly,
the substitution of R1152 of the CBD with Glu (referred to as the
‘‘R2E’’ mutant of the CBD) essentially disrupted the entire site II
interaction between the myosin VI CBD and Dab2 (KD 310 nM
for the R1152E-CBD/Dab2 MIR complex versus KD 420 nM
for the wild-type CBD in complex with the aA0 half of the MIR;
Figures 2C and 5D), indicating that the charge-charge interac-
tions in site II play critical roles in the binding specificity between
myosin VI and Dab2. Most importantly, the interactions in site II
play a modulatory role in converting myosin VI from a monomer
in its apo-form into a transport-competent dimer upon binding
to Dab2 on clathrin-coated vesicles.
The Myosin VI/Dab2 Interaction Is Essential for Myosin
VI/Clathrin-Coated Vesicle Colocalization
The role of the interaction between the myosin VI CBD and Dab2
in the localization of the motor on clathrin-coated vesicles was
investigated by transiently expressing the wild-type myosin VI
tail domain-containing CBD (residues 1040–end) or its L2K,
R2E mutants in HeLa cells. As described previously (Buss
et al., 2001; Dance et al., 2004; Spudich et al., 2007), the GFP-
fused wild-type myosin VI CBD colocalizes well with the cla-
thrin-coated vesicles (Figure 6A1). In contrast, the substitution
of L1209 with Lys, which essentially disrupts the interaction
between myosin VI and Dab2 (Figure 5), led to a loss of colocal-
ization of the myosin VI CBD to the clathrin-coated vesicles
(Figure 6A2), indicating that direct binding between myosin VI
and Dab2 is essential for the motor to transport the clathrin-
coated vesicles. It is important to note that the R1152E mutant
of the myosin VI CBD also did not show any colocalization with
the clathrin-coated vesicles (Figure 6A2), even though the
mutant CBD binds to Dab2 with reasonably high affinity (KD
310 nM, Figure 5D). These data suggest that the Dab2
binding-mediated dimerization of the myosin VI CBD is required
for the motor to be colocalized with the clathrin-coated vesicles.
Taken together, our data demonstrate that the specific interac-
tions between CBD and Dab2 (seen in both site I and site II)
are critical for myosin VI-mediated clathrin-coated vesicle endo-
cytosis.
DISCUSSION
Being the only known minus-ended actin-based molecular
motor, myosin VI plays essential roles in a host of cellular func-
tions. Adding complexities to the motor functions, myosin VI is
known to exist both in nonprocessive monomer form and pro-
cessive dimer form in cells. Recent structural and biophysical
studies have elucidated the molecular basis governing theCell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc. 543
Figure 5. The Details of the Binding between the Myosin VI CBD and the Dab2 MIR
(A) Surface diagram of the myosin VI CBD/Dab2 MIR complex shown in an open-book style. In this presentation, the hydrophobic amino acid residues are drawn
in yellow, the positively charged residues in blue, the negatively charged residues in red, and the uncharged polar residues in gray.
(B and C) Detailed molecular interactions between the myosin VI CBD and the Dab2 MIR using the same color scheme as that in Figure 3A.
(D) ITC-based measurements of the interactions between the Dab2 MIR with a ‘‘site I’’ mutant (L1209K) and a ‘‘site II’’ mutant (R1152E) of the myosin VI CBD.reverse directionality of the motor (Bryant et al., 2007; Menetrey
et al., 2005). The most challenging question remaining to be
answered for myosin VI is perhaps the molecular mechanism
that regulates the monomer-dimer conversion of the motor.
The structural studies described here clearly demonstrate that
myosin VI undergoes a cargo binding-regulated monomer-to-
dimer conversion. Before binding to cargoes (the clathrin-coated
vesicle adaptor Dab2 in this case), the myosin VI CBD adopts a
stable monomer. Upon binding to Dab2, an extended myosin VI-
interaction region of Dab2 tethers myosin VI into a stable dimer. It
is interesting to note that the Dab2 MIR exists as an unfolded
monomer before binding to the myosin VI CBD. Therefore, the
conversion of the myosin VI monomer from its cargo-free form
to a Dab2-bound dimer is a result of the synergistic actions of
both myosin VI and its cargo, rather than the dimerization of
the motor by binding to a pre-existing dimeric adaptor (Fig-
ure 6B). It should be noted that the tail domain of myosin VI
contains another subdomain (80 residues) immediately pro-
ceeding CBD characterized here, and this subdomain has
been shown to bind to lipid membranes as well as other cargoes
including GIPC and optineurin (Reed et al., 2005; Sahlender
et al., 2005; Spudich et al., 2007). The interaction of this subdo-
main with lipid membranes would increase the local concentra-
tion of the motor and thereby might promote dimerization of
myosin VI on the cargo vesicles.
Cargo-mediated dimerization might be a common processiv-
ity regulatory mechanism for many molecular motors. For
example, myosin VII does not contain the central coiled-coil
domain found in known dimeric myosins, and the hypothetical544 Cell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc.central coiled-coil domain of myosin X was found to form an
extended monomeric a helix instead of a coiled-coil dimer
(Knight et al., 2005). Yet both myosin VII and myosin X need to
form processive dimers for actin-based cargo transport (Knight
et al., 2005; Yang et al., 2006). It is possible that both myosin
VII and myosin X employ a similar cargo-binding regulated
monomer-to-dimer conversion as that of myosin VI, although
the detailed molecular mechanisms governing such anticipated
conversions remain to be elucidated. The cargo binding-induced
dimerization is not limited to actin-based motors. KIF1A/Unc104
has been found to exist as a nonprocessive monomer in solution.
Its C-terminal CBD-mediated binding to PI(4,5)P2-containing
rafts converts the motor into a processive dimer that is required
for vesicle transport (Kikkawa et al., 2000; Klopfenstein et al.,
2002; Tomishige et al., 2002). It remains to be established
whether certain adaptor protein(s) in addition to PI(4,5)P2 on
the vesicles are also required for the KIF1A dimer formation.
The structure of the myosin VI/Dab2 complex determined here
reveals that the myosin CBD contains two discrete Dab2-binding
sites (sites I and II, Figure 5). The extensive hydrophobic interac-
tions provide the majority of the binding energy for the mysoin VI/
Dab2 complex. Interestingly, although the charge-charge inter-
actions in site II only play a minor role in the contribution to the
binding energy, these interactions are absolutely required for
the Dab2 binding-induced dimer formation of myosin VI. Since
charge-charge interactions are generally much more specific
than hydrophobic interactions, we speculate that myosin VI
(and perhaps other myosin motors) could form either processive
dimers or nonprocessive monomers in response to its specific
Figure 6. CBD/Dab2 Interaction Is Required for the Colocalization
of Myosin VI with Clathrin-Coated Vesicles
(A) Transient expressed GFP-long CBD (i.e., CBD containing an N-terminal
extension, residues 1040–end) forms clusters and colocalizes with clathrin-
coated vesicles in HeLa cells (A1). Insets highlight the colocalization between
the myosin CBD and clathrin-coated vesicles. Disruption of the CBD/Dab2
interaction by substitution of L1209 with Lys (‘‘long-CBD L2K’’) leads to
complete disappearance of the colocalization of the myosin VI CBD with the
clathrin-coated vesicles (A2). Disruption of the interaction in site II (R1152E
mutation of the CBD) also disrupts the colocalization of the myosin VI CBD
with the clathrin-coated vesicles (A3). It is noted that both mutants of the
myosin VI CBD are more diffused than the wild-type CBD when expressed
in HeLa cells. The scale bar represents 5 mm.
(B) A schematic model showing the Dab2-mediated dimerization of myosin VI
during the vesicle/cargo transport. The myosin VI CBD/Dab2 MIR complex is
shown in the combined surface and ribbon representations. Other domains of
myosin VI and Dab2 are simplified with cartoon representations. The step size
between the two heads of myosin VI is 36 nm. The dimerization of myosin VI
is mediated by the synergistic binding between the myosin VI CBD and the
Dab2 MIR rather than preformed dimeric cargo adaptors.cargoes. For example, myosin VI may stay as a nonprocessive
monomer if its cargo binding is restricted to site I only. Such
monomeric myosin VI/cargo complex formation would be ex-
pected to be important for the structural roles of the motor
(e.g., connecting cytoskeletons with membranes).
We note with surprise that the interaction between myosin VI
and Dab2 is very strong (KD 50 nM). Such a strong motor/cargo
interaction is somewhat odd, considering the reversible cargo
loading and unloading processes required for motor-mediated
cargo transport. With such strong binding affinity, it would be
difficult for myosin VI-bound Dab2 to dissociate from the motor,
given that cellular concentrations of both myosin VI and Dab2 are
quite high (Fazili et al., 1999; Hasson and Mooseker, 1994; Rodri-
guez and Cheney, 2000). It is possible and logically necessary
that myosin VI employs some sort of regulatory switch to regu-
late Dab2-containing cargo loading and unloading. For example,
the Dab2 MIR contains several absolutely conserved amino acid
residues that can be phosphorylated (e.g., T676, S682, and
Y683), and these residues are intimately involved in the interac-
tion with the myosin VI CBD. Based on the structure of the
myosin VI/Dab2 complex, the phosphorylation of one or more
of these residues would weaken the interaction between the
motor and its cargo and thus would facilitate the unloading of
the cargo. The identification of such potential phosphorylation-
dependent cargo unloading switches of myosin VI represents
an important line of future work.
Finally, the elucidation of the interaction mechanism between
myosin VI and Dab2 represents a good example of combining
two major structural biology techniques, namely NMR spectros-
copy and X-ray crystallography, in tackling challenging biolog-
ical questions. We believe that the combined efforts of NMR
spectroscopy and X-ray crystallography can play a larger role
in answering challenging biological questions.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The mouse myosin VI CBD (residue 1137–end) fused with His6-tag was ex-
pressed in E. coli BL21 (DE3) in its native form. The fusion protein was purified
by Ni2+-NTA affinity chromatography. After removing His6-tag, protein was
further purified by size-exclusion chromatography. The NMR samples were
concentrated to 0.2 mM (for sample condition screening and titration exper-
iments) or 1 mM (for structural determinations) in 100 mM sodium phosphate
(pH 6.5), 2 mM DTT, and 2 mM EDTA. All point mutants of the myosin VI CBD
described in this study were prepared using PCR-based methods and purified
using essentially the same method as used for the wild-type protein. The rat
Dab2 MIR (residues 675–713) and the MIR aA0 (residues 675–695) (both fused
with GB1-tag) were expressed in E. coli BL21 (DE3) and purified by Ni2+-NTA
affinity chromatography followed by size-exclusion chromatography. For the
complex structure determination, the Dab2 MIR was fused to either the N or
C terminus of the myosin VI CBD with different lengths of flexible (GS)-linkers
coupled with a thrombin cleavage site (‘‘LVPRGS’’) in the middle. The myosin
VI CBD/Dab2 MIR complex proteins were purified using the same procedure
for the myosin VI CBD, and the flexible linker was cleaved by thrombin. The
protease in the digestion mixture was removed by another step of gel-filtration
chromatography.
NMR Spectroscopy and Structure Calculations
NMR spectra were acquired at 30C on Varian Inova 500 or 750 MHz spe-
ctrometers each equipped with a z-axis shielded triple resonance probe-
head. Backbone and nonaromatic, nonexchangeable side chain resonanceCell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc. 545
assignments of myosin VI L2K-CBD were achieved by standard heteronuclear
correlation experiments using 15N/13C-labeled samples and confirmed by a 3D
15N-separated NOESY experiment using 15N-labeled samples (Bax and Grze-
siek, 1993; Kay and Gardner, 1997). The side chains of aromatics were as-
signed by 1H 2D NMR experiments using unlabeled samples in D2O (Wuthrich,
1986). Approximate inter-proton distance restraints were derived from 2D 1H-
NOESY, 3D 15N-seperated NOESY, and 3D 13C-seperated NOESY spectra.
Hydrogen bonding and backbone dihedral angle restraints were generated
as described in our earlier work (Feng et al., 2004). Structures were calculated
using the program CNS (Brunger et al., 1998).
Crystallography
Crystals of the myosin VI CBD/Dab2 MIR complex were obtained by the
hanging drop vapor diffusion method at 16C. To set up a hanging drop, 1 ml
of concentrated protein solution was mixed with 1 ml of crystallization solution
with 20% PEG3350, 0.2 M potassium thiocyanate, or 0.2 M sodium iodide
(pH 7.0) buffer. Before X-ray diffraction, crystals were soaked in crystallization
solution containing 20% glycerol for cryoprotection. The diffraction data of
native and iodine derivative crystals were collected at 100 K on a Rigaku RAXIS
IV++ imaging-plate system with a MicroMax-007 copper rotating-anode
generator. The data were processed and scaled using the MOSFLM and
SCALA in the CCP4 suite (CCP4, 1994). We failed to solve the complex struc-
ture by the molecular replacement method using the NMR structure of myosin
VI L2K-CBD as the search model. The NaI data set was then used for heavy
atom substructure determination. Four iodine sites were found by SHELXD
(Sheldrick, 2008). The site refinement and phase improvement were carried
out by autoSHARP (Vonrhein et al., 2007). The program Molrep (Vagin and
Teplyakov, 2000) was then employed for searching the CBD model derived
from the NMR structure in the density map. After four CBD models were
located, the backbone was rebuilt manually based on the density map to
produce an initial model. With the combination of phase information from
the initial model, the phase was further improved by RESOLVE (Terwilliger,
2000) and used as the input for ARP/wARP model building (Perrakis et al.,
1999). The output model was refined in Refmac5 (Vagin et al., 2004) against
the 2.2 A˚ native data set. COOT was used for model rebuilding and adjust-
ments (Emsley and Cowtan, 2004).
Isothermal Titration Calorimetry Assay
Isothermal titration calorimetry (ITC) measurements were carried out on a VP-
ITC Microcal calorimeter (Microcal) at 25C. All protein samples were in 50 mM
(pH 6.5) phosphate buffer. The titration processes were performed by injecting
5–10 ml aliquots of the myosin VI CBD into Dab2 proteins (or GB1 as the
control) at time intervals of 2 min to ensure that the titration peak returned to
the baseline. The titration data were analyzed using the program Origin7.0
and fitted by the one-site binding model.
Disufide-Mediated Chemical Crosslinking
Myosin VI CBD(L1225C) and the myosin VI CBD(L1225C)/Dab2 MIR complex
were purified using the method described for the wild-type CBD counterparts.
The Dab2 MIR aA0 peptide was directly added into the myosin VI CBD(L1225C)
to make the myosin VI CBD(L1225C)/Dab2 MIR aA0 peptide complex. To
initiate chemical crosslinking, DTT was removed from the protein samples
by gel filtration and the samples were left at room temperature with or without
addition of [Cu(Phen)3]2+ ([Cu(1,10-phenanthroline)3]
2+ (0.75 mM final concen-
tration) for 20 min. The concentration of the proteins used in the assay was
25 mM. All the samples were mixed with SDS loading buffer without or with
10 mM DTT at final concentration and analyzed by SDS-PAGE.
Cell Culture and Imaging
The globular tail domain of myosin VI containing CBD (residues 1040–end) and
its mutants were individually cloned into a modified pEGFP-C3 vector (Invitro-
gen). HeLa cells were transfected with 0.5 mg of each form of CBD plasmids
per well using the Lipofetamine Plus transfection kit (Invitrogen) and were
subsequently cultured for 24 hr before fixation by 4% paraformaldehyde
(PFA) and permeabilization with 0.2% Triton X-100 in PBS. After washing
with PBS, cells were incubated with primary (mouse monoclonal antibody
X22 to clathrin, abcam) and rhodamine red X-conjugated secondary antibody546 Cell 138, 537–548, August 7, 2009 ª2009 Elsevier Inc.(anti-mouse, Jackson’s Laboratory). The images were acquired on a Nikon
TE2000E inverted fluorescent microscope.
Illustrations
The protein structure figures were prepared using the programs MOLMOL
(Koradi et al., 1996), MOLSCRIPT (Kraulis, 1991), PyMOL (http://pymol.
sourceforge.net/), and GRASP (Nicholls, 1992).
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The atomic coordinates of the myosin VI L2K-CBD and the myosin VI CBD in
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